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Abstract
Breast cancer metastasis is the main cause for mortality in breast cancer patients.
However, knowledge of metastatic recurrence is limited, and there is a need to
understand metastatic recurrence in order to treat breast cancer patients more
effectively. Highly invasive metastatic breast cancer has shown to exhibit metabolic
adaptability, transitioning from glycolysis to oxidative phosphorylation in the presence of
microenvironmental stress. NADH and FAD are naturally occurring cofactor products
during glycolysis and oxidative phosphorylation, respectively, and they are of particular
importance during these metabolic processes due to their endogenous fluorescence.
Measuring the ratio of fluorescence intensities of these cofactors through a redox ratio
allows for the quantification of the comparative levels of glycolysis and oxidative
phosphorylation occurring in breast cancer cells. Two-photon imaging was used to
assess the redox ratio of 4T1KOT, a variant of highly metastatic 4T1 cells with deletion
of the TWIST gene, a gene known to promote metastasis. This thesis reports that
4T1KOT cells, compared to metastatic 4T1 cells, have a decreased redox ratio at
normoxia conditions, and they also lose their metabolic adaptability under hypoxiareoxygenation stress. This study demonstrates that metabolic adaptability to hypoxiareoxygenation stress could be used as a biomarker for breast cancer metastatic
potential.
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Background
Cancer metastasis to other organ systems is the leading cause of mortality in
breast cancer patients [1]. Currently, there is very little knowledge of metastatic
recurrence in breast cancer; it is necessary to understand markers of metastatic
recurrence in breast cancer so that patients receive appropriate treatment based on
metastatic potential of the primary tumor [2]. A current method for assessing the
benefits of chemotherapy, and thus the risk of metastatic recurrence, is the Oncotype
DX. The Oncotype DX uses an analysis of 16 breast cancer genes identified in literature
as important indicators of metastatic recurrence and compares these genes with 5
reference genes not linked to metastatic recurrence, producing a score to assess the
benefit of chemotherapy treatment [3]. However, the Oncotype DX is expensive
(~$4000 per test), not available at all medical centers, and not able to be used for all
tumor receptor statuses and sizes [4]. Therefore, there is still a need to determine
markers for metastatic potential in breast cancer cells.
A common metabolic characteristic of cancer cells is the Warburg Effect, a
discovery that tumor cells tend to rely more on glycolysis over oxidative phosphorylation
in order to meet their energy needs [5]. However, recent studies have concluded that
highly invasive cancer cells favor oxidative phosphorylation over glycolysis, using the
extra energy to migrate to other organs in the body [6-7]. One of these studies explored
metabolic features of metastatic cancer cells, particularly regarding the changes in
metabolism that highly invasive breast cancer cells exhibit in response to
microenvironmental stress [7]. Compared to cancer cells proliferating in either the
breast tissue or another target organ, cancer cells migrating through the bloodstream
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exhibited higher levels of oxidative phosphorylation, while the proliferating cancer cells
were more glycolytic (Figure 1) [7]. A clinical application would need to be able to detect
invasive cancers based on metabolic activity of the primary tumor and not circulating
cancer cells. The study thus investigated primary cancer cells from three invasive breast
cancer cell lines and found that hypoxia-reoxygenation, a microenvironmental stressor,
upregulated PGC-1α expression in these proliferating cancer cells (Figure 1); PGC-1α is
a gene that promotes oxidative phosphorylation [7]. Furthermore, acute hypoxia has
been noted in another study to produce an environment more conducive to migration for
cancer cells [8]. The study by LeBleu et. al [7] made us ask the question of whether this
increase in oxidative phosphorylation triggered by microenvironmental stress was
inherent of all breast cancer cells or just metastatic breast cancer cells.

B
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Figure 1
A:
B:

Primary cancer cells (PCC’s), circulating cancer cells (CCC’s), and lung
metastatic cancer cells (MCC’s) are illustrated [7].
Heat map illustrating expression of common genes between PCC’s, CCC’s, and
MCC’s that are related to oxidative phosphorylation. A Z-score approaching 1
(red) corresponded with greater oxidative phosphorylation levels. Migratory
CCC’s exhibited much greater levels of oxidative phosphorylation compared to
proliferative PCC’s and MCC’s [7].
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C:

PGC-1α expression levels of three highly invasive breast cancer cell lines under
two conditions: Normoxia (21% O2 ) and Hypoxia-Reoxygenation (48 hours 1-2%
O2 , 24 hours 21% O2 ). The metastatic cell lines exhibited metabolic adaptability,
increasing their oxidative phosphorylation in the presence of microenvironmental
stress (hypoxia-reoxygenation) [7].
Nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide

(FAD) are two major cofactor products that occur in glycolysis and oxidative
phosphorylation, respectively (Figure 2). These two cofactors are of importance due to
their endogenous fluorescence [9]. During glycolysis, NAD is reduced to NADH in the
cytoplasm; during oxidative phosphorylation, which occurs in the mitochondria, NADH is
oxidized to NAD+ and FADH2 is oxidized to FAD [4]. Because NADH and FAD are the
only forms of these cofactors that have endogenous fluorescence, a redox ratio of
fluorescence intensities of NADH and FAD (Figure 2), calculated through optical
imaging methods like two-photon microscopy, allows for a quantification of the relative
levels of glycolysis and oxidative phosphorylation occurring in the cell [10]. A past study
in our lab found that the redox ratio changed in response to common mitochondrial
drugs that affect the electron transport chain [4].

B

A
Redox Ratio Defined As
[FAD]
[FAD]+[NADH]
0
Glycolysis

1

Oxidative
Phosphorylation

Figure 2
A:

The schematic on the left illustrates the roles of fluorescent NADH and FAD
during metabolism. The equation on the right illustrates how we define our redox
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ratio, with a higher redox ratio indicating greater levels of oxidative
phosphorylation occurring in the cell.
B:

This experiment tracked the changes in redox ratio in responses to common
mitochondrial drugs. Oligomycin inhibits Complex II, which drives down [FAD],
decreasing redox ratio. FCCP drives the consumption of NADH by Complex I,
increasing the redox ratio. Antimycin A/Rotenone inhibits Complex I, decreasing
the redox ratio [4].

A recent study in our lab sought to assess the change in redox ratio in a panel
of isogenic triple negative breast cancer cells with varying metastatic potential. The
results of the study found that not only does the normoxic redox ratio decrease as
metastatic potential decreases, but also the metabolic adaptability decreases as
metastatic potential decreases [4]. This study caused us to further investigate the
possible link between metabolic adaptability to microenvironmental stress and
metastasis by posing the question of how deletion of a metastasis-promoting gene in
highly invasive 4T1 cells would affect their metabolic adaptability.
TWIST is a gene that has been linked to metastatic potential through epithelial
to mesenchymal transition [11]. A past study demonstrated that inhibition of TWIST in
4T1 cells resulted in significantly less metastatic nodes in the lungs of the Balb/c mice.
Furthermore, this study noted that 70% of human invasive lobular carcinomas have
been found to express TWIST, signifying the clinical relevance of this metastasispromoting gene [11].
CRISPR/Cas9 gene editing allows for simple, permanent removal of target
gene sequences. Derived from bacterial immune defense, the CRISPR/Cas9 system,
combined with a 20-nucleotide single guide RNA (sgRNA) for base pair recognition,
utilizes the Cas9 enzyme to cleave the desired target 20-base pair DNA sequence [12].
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This method of DNA modification allows for the development of a permanent 4T1 cell
line with the TWIST gene deleted.

Methods
Breast Cancer Cell Culture
Breast cancer cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) while also adding 10% fetal bovine serum (FBS), 2 mM of L-Glutamine, 1%
penicillin-streptomycin (Pen-strep), and 1% nonessential amino acids (NEAA) [4]. Cells
were placed in an incubator with conditions of 37⁰ C, 21% O2 , and 5% CO2 . Upon
reaching 70-80% confluency, cells were passaged into a new T75 flask.

CRISPR/Cas9 Deletion of TWIST and Clonal Selection
Using the sgRNA guide tool provided by the Zhang laboratory (MIT,
Cambridge, MA), the 20-base pair sgRNA was identified to target the TWIST gene, also
known as the Twist1 gene, in 4T1 mouse cells. The sgRNA was cloned into pCasGuide-EF1a-GFP plasmids through the services of OriGene (Rockville, MD). These
plasmids were expanded using E. Coli bacteria, and plasmid isolation from E. Coli was
achieved using the QIAGEN Plasmid Maxi Kit. For plasmid transfection, 4T1 cells were
seeded in a 6-well plate at a concentration of one million cells/well and incubated for 24
hours. 10 μg of plasmid were added to Lipofectamine 3000 and added to the 4T1 cells.
After 24 to 48 hours, green fluorescent protein (GFP) signal was detected using a Nikon
TiE fluorescence microscope workstation with a CoolSnap HQ2 camera; signals
exhibiting GFP expression indicated the transfected cells, as the plasmid contained

7

GFP. Transfected 4T1 cells were suspended in a PBS solution at a concentration of two
million cells per mL. The transfected cells were filtered through a 50 μm filter into a
FACS tube. Cell sorting was achieved through the FACS Aria III System (BD
Biosciences, San Jose, CA). The 5% of transfected cells that exhibited the greatest
GFP expression were sorted to have cells with the highest CRIPSR/Cas9 plasmid
concentration. The sorted cells were incubated and cultured for 7 to 14 days in the
same incubation settings described above. The cell colonies were then cloned into 13
clones to produce a population that had the least TWIST expression.

Flow Cytometry Preparation Protocol to Detect TWIST Expression
The protocol is summarized below (Figure 3). A primary TWIST antibody
(TWIST2C1a) was purchased from Santa Cruz Biotechnologies (Dallas, TX). In
addition, an appropriate fluorescent secondary antibody (sc-2078) was also purchased
through Santa Cruz. After obtaining 3 million cells in media, cells were centrifuged
400xg for 5 minutes to remove residual media; all subsequent centrifuges were at the
same settings. The cells were resuspended in 1 mL PBS and centrifuged. The cells
were then resuspended in 1 mL of 5x TF Perm/Wash Buffer (diluted in DI water) and
centrifuged. Resuspension then occurred in 250 μL of 4x TF Fix/Perm (diluted in diluent
buffer) and incubated in the dark at 4⁰ C for one hour. The cells were washed and
centrifuged twice with 1 mL TF Perm/Wash. After resuspension in 500 μL of
Perm/Wash, the volume was split into 3 polystyrene tubes, each labelled either
experimental, isotype control, or negative control. 30 μL of primary antibody was added
to the experimental tube, and all tubes were incubated in the dark at 4⁰ C for 1 hour.
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After 2 more washes after incubation, 4 μL of secondary antibody was added to the
experimental and isotype control tubes and incubated with the same conditions used for
the primary antibody. The cells were then washed twice again and resuspended in 500
μL of Perm/Wash. Flow cytometry was performed using a flow cytometer from BD
Biosciences.

Important Materials
4x TF Perm/Fix
5x TF Perm/Wash
Primary Antibody (PA)
Secondary Antibody (SA)

3 million cells in
one 15 mL tube

Centrifuge

Centrifuge Settings
400xg
5 minutes
Incubation Settings
4⁰ C in dark
1 hour

Resuspend in 1
mL PBS

Centrifuge

Resuspend in 1
mL Perm/Wash

Centrifuge

Resuspend in 500
mL Perm/Wash

Centrifuge 2x

Incubate

Wash twice with 1
mL Perm/Wash

Resuspend in 250
μL Perm/Fix

Aliquot 166 μL into three

tubes: label “exp”, “iso
control”, “neg control”
Add 30 μL PA to
exp tube

Incubate

Wash twice with 1
mL Perm/Wash

Centrifuge 2x

Add 4 μL SA to
exp and iso tubes

Incubate

Ready for Flow
Cytometry

Resuspend in 500
μL Perm/Wash

Centrifuge 2x

Wash twice with 1
mL Perm/Wash

Figure 3: Flow chart for preparation of cells for flow cytometry analysis for TWIST
expression.
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Lysate Preparation for Western Blot Analysis for TWIST Expression
Breast cancer cells were cultured and placed in a 6-well plate with a seeding
density of 250,000 cells/well and incubated for 24 hours. After incubation, 75 μL of
protein buffer was added to each well and accumulated using a cell scraper. The
solution was filtered in a microcentrifuge tube and centrifuged at 3500 RPM for 3
minutes. The lysate solution was stored at -80⁰ C until Western Blot Analysis was
performed.

Normoxia and Hypoxia-Reoxygenation Protocols for Two-Photon Microscopy
Normoxia conditions were defined as the oxygen level during standard
incubation (21% O2 ), while hypoxia-reoxygenation conditions were defined as one hour
of chronic hypoxia (0.5% O2 ) followed by one hour of reoxygenation in the incubator
(21% O2 ). Hypoxia-reoxygenation was achieved through the Oxycycler C42, a system
that controls various levels of oxygen, nitrogen, and carbon dioxide through software;
both the system and software were created by BioSpherix (Parish, NY).

Two-Photon Microscopy of 4T1-TWIST Knockout (4T1KOT) Cells
4T1KOT cells were cultured and plated on glass slides in 6 individual 35 mm
petri dishes at a seeding density of 150,000 cells/mL. The cells incubated for
approximately 72 hours until they reached 70-80% confluency. 3 petri dishes were
designated for the normoxia condition, while 3 petri dishes were designated for the
hypoxia-reoxygenation condition. 3 fields of view were taken for each dish, resulting in 9
total images for each condition. Images were taken on a custom-built multiphoton
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microscope using a 20X water immersion objective lens with a 4X optical zoom. Images
were 512 x 512 pixels with a 16-bit depth and a field of view of 130 μm x 130 μm. NADH
was excited at 755 nm with resulting emission spectra of 460/40 nm; FAD was excited
at 860 nm with resulting emission spectra of 525/40 nm. NADH and FAD were imaged
at power settings of 30 mW and 40 mW, respectively. Images were analyzed in
MATLAB by taking the average NADH and FAD intensity of 6 randomly circled cells in
the image and calculating the redox ratio using these intensities values. The two-photon
microscope protocol is summarized below (Figure 4).
Cells plated at
150,000 cells/well

6 plates

3 plates

3 plates
Hypoxia
Reoxygenation
1 hr 0.5% O2
1 hr 21% O2

Normoxia
21% O2

3 images per
plate
Excitation
NADH
(30 mw)

Emission

Excitation
FAD
(40 mw)

460/40 nm

755 nm
Emission
860 nm

525/40 nm

Figure 4: Two-photon imaging protocol for 4T1KOT Cells. Power settings for NADH
and FAD are listed under their respective names in parentheses.
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Statistical Analysis
One-way ANOVA was used for analysis for the Western Blots, and a nested,
two-way ANOVA was used for the redox ratio data.

Results
TWIST Expression Decreases as Metastatic Potential Decreases

TWIST (25 kDa)

Ponceau S (45 kDa)

Metastatic Potential

Figure 5: Bar plot and Western Blot illustrating TWIST expression in 4T1, 4T07, and
168FARN. The figure also notes the metastatic potential of the cell lines, and the data
suggests that TWIST expression could be linked to metastatic potential. Ponceau S is
the reference protein used in the Western Blot. Error bars indicate the standard error of
the mean TWIST expression level. The representative blots are derived from the same
gel and image. * indicates p<0.05.
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CRISPR/Cas9 editing produces a 4T1 cell line with decreased TWIST expression

A

B

TWIST (25 kDa)
Ponceau S (45 kDa)

Figure 6
A:

Bar plot and Western Blot images of 4T1 and several of the possible 4T1KOT
clones created through clonal selection. Clones were named after the respective
well in which they were originally seeded in a 96-well plate. Ponceau S is the
reference protein for the Western Blot data. Error bars indicate standard error of
the mean TWIST expression level for each cell line.

B:

Bar plot and Western Blot images results comparing TWIST expression of 4T1 to
Clone A2, the clone we chose to be our 4T1KOT cell line. The results are
normalized, with the 4T1 TWIST expression denoted as 1. 4T1KOT was
achieved through CRISPR/Cas9 deletion and clonal selection. Error bar indicates
the standard error of the mean TWIST expression level. Western blot images are
derived from the same gel and image; the original image is shown in Figure 6A.
* indicates significance at the level p < 0.05.
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Deletion of TWIST from 4T1 Cells Decreases Redox Ratio and Eliminates Metabolic
Adaptability

A
4T1

4T1KOT

168FARN

Normoxia

50 μm

Hypoxia
Reoxygenation

B

C

Figure 7
A:

Redox Images of 4T1, 168FARN, and the 4T1 TWIST Knockout (4T1KOT) cell
lines during normoxia and hypoxia-reoxygenation. The images show an increase
in redox ratio for 4T1 after hypoxic stress, while no change in redox ratio for the
less metastatic 168FARN. In addition, normoxia redox ratio is decreased for the
non-metastatic breast cancer cell line 168FARN. 4T1KOT produces redox
images similar to 168FARN.

B:

Bar plot of the redox ratio of the three cell lines during normoxia and hypoxiareoxygenation conditions. The data suggests both a decrease in optical redox
ratio and a loss of metabolic adaptability upon loss of metastatic ability due to
14

TWIST deletion. Error bars indicate the standard deviation of the mean redox
ratio. *** Denotes statistical significance at the level p<0.001.
C:

Bar plot of the post-hypoxia change in redox ratio of the three cell lines, our
measure of metabolic adaptability. Error bars indicate the standard deviation,
calculated as √(𝑠1)2 + (𝑠2)2 , where s1 and s2 are standard deviations of the
redox ratio of the cell line at normoxia and hypoxia-reoxygenation, respectively.
4T1 and 168FARN images were gathered during a previous study in our lab
[4].

Discussion / Conclusion
While the flow cytometry protocol could detect positive TWIST expression in 4T1
cells (Appendix), we opted to do Western Blots due to the efficiency that the procedure
provides that flow cytometry didn’t. Lysates could be frozen down and used at the same
time conveniently; however, all 13 clones, 4T1 cells, and a negative control cell line
would have to be 70-80% confluent in culture at the same time for flow cytometry, which
is very difficult to obtain in terms of cell culture.
Lessons learned from producing the flow cytometry protocol were very important
for possible future uses. The protocol provided by the Zaharoff lab at the University of
Arkansas originally called for a 0.2% Triton solution to act as the detergent; however,
the detergent was killing our 4T1 cells prior to flow cytometry. After consultation with
graduate students in the Zaharoff lab, we changed the detergent from a 0.2% Triton
solution to the 4X TF Perm/Fix in order to simultaneously permeabilize and fix the cells
to avoid cell death. Another issue we ran into was the identification of appropriate
antibodies. We ultimately found a very commonly used TWIST primary antibody in
literature; while many companies offered TWIST antibodies, Santa Cruz had by far the
most publications with their antibody.
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The Western Blot data regarding three breast cancer cell lines of varying
metastatic potential is in consistency with the description of TWIST as a promoter of
metastasis [11]. The Western Blot data of the 4T1KOT clones illustrates that we have
developed a population of 4T1 cells that have varying levels of TWIST expression, and
this provides us with the ability to add more data points to assess metabolic adaptability
of 4T1 cells as a function of TWIST expression levels in the future. It is important to note
that 4T1KOT (Clone A2), the clone we chose to model as our TWIST knockout cell line,
still has some expression of TWIST. We believe this TWIST expression is due to the
heterogeneity of the cell line, as some 4T1 cells with TWIST not deleted are likely to
exist past the CRISPR/Cas9 process.
Based on the redox data, we have shown that metabolic adaptability in response
to our hypoxia-reoxygenation stress test is a marker for metastatic potential. To support
past research that compared metastatic and non-metastatic breast cancer cell lines, this
study deleted TWIST, a metastasis-promoting gene, from the 4T1 genome [4,11].
Deletion of this metastasis-promoting gene not only reduced the normoxia redox ratio of
4T1 cells, but it also eliminated 4T1’s metabolic adaptability to the hypoxiareoxygenation stress test. Comparatively, the 4T1KOT’s metabolic profile during
normoxia and hypoxia-reoxygenation now resembles non-metastatic 168FARN [4].
Future studies will seek to examine the 4T1KOT cell line in vivo. We will be
injecting mice with 4T1 and 4T1KOT cells to assess metastatic nodes in the lung, an
experiment similar to the study done by Yang et. al [11]. In addition, future studies will
seek to assess the redox ratio of human breast cancer cell lines of varying metastatic
ability and determine their metabolic adaptability to the hypoxia-reoxygenation stress
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test. Future work will also focus on redox imaging of primary tumors derived from mice
under the same conditions as in vitro studies.
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Appendix

Figure 8:
Flow cytometry graphs that demonstrate 4T1 TWIST expression. “4T1-Negative” is a
flow cytometry plot of 4T1 cells that received neither the primary nor the secondary
antibody. “4T1-Iso” is a flow cytometry plot of 4T1 cells that received only the secondary
antibody; this plot accounts for any non-specific binding of the secondary antibody that
would contribute to a false positive TWIST expression. “4T1-Sample SC” is the flow
cytometry plot of 4T1 cells incubated with both primary and secondary antibodies; SC
stands for Santa Cruz, the company that provided the antibodies. Secondary antibody
fluorescence was detected in the FITC Channel (Max excitation = 494 nm, Max
emission = 520 nm), and positive TWIST expression was defined as the portion of the
plot located in Quadrant P4. The plots demonstrate that the flow cytometry protocol
described in the Methods section was successful in identifying TWIST expression in
4T1 cells.
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